Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
Notified -
Globe Newswire8-10-2025, 18:09
‘Hong Kong Summer Viva’: Calling All Fans to Dive into Festivals, Games and Parties – Only in Hong Kong! 31-05-2025, 01:31
